{
    "clinical_study": {
        "@rank": "124567", 
        "arm_group": {
            "arm_group_label": "Omega-3 fatty acid ethyl esters 2 g", 
            "description": "Omega-3 fatty acid ethyl esters 2 g, administered orally once or twice daily after meals"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of long-term use of\n      granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules)\n      in patients with hyperlipidemia in daily medical practice"
        }, 
        "brief_title": "Evaluation of the Safety and Efficacy of Long-term Use of Lotriga", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hyperlipidemia", 
        "condition_browse": {
            "mesh_term": "Hyperlipidemias"
        }, 
        "detailed_description": {
            "textblock": "This special drug use surveillance on long-term use of granular capsule formulation of\n      omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) was designed to investigate the\n      frequency of adverse events in patients with hyperlipidemia The usual adult dosage is 2 g of\n      omega-3 fatty acid ethyl esters administered orally once daily after meals. However, the\n      dosage can be increased up to twice daily (at a dose of 2 g) depending on the patient's\n      triglyceride level."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with hyperlipidemia\n\n        Exclusion Criteria:\n\n          -  (1) Patients with hemorrhage (e.g., hemophilia, capillary fragility, gastrointestinal\n             ulcer, urinary tract hemorrhage, hemoptysis, or vitreous hemorrhage) (2) Patients\n             with a history of hypersensitivity to ingredients in Lotriga Granular Capsules"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Hyperlipidemia"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02153073", 
            "org_study_id": "142-011"
        }, 
        "intervention": {
            "arm_group_label": "Omega-3 fatty acid ethyl esters 2 g", 
            "description": "Omega-3 fatty acid ethyl esters granular capsules", 
            "intervention_name": "Omega-3 fatty acid ethyl esters", 
            "intervention_type": "Drug", 
            "other_name": "Lotriga Granular Capsules"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Lotriga Granular Capsules Special Drug Use Surveillance (Long-term Use Survey)", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "+1-800-778-2860 (USA & EU)"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The frequencies of all adverse events observed during the observation period will be tabulated by type and seriousness. Adverse events are defined as unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product, regardless of relationship to the medicinal product.", 
            "measure": "Frequency of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "For 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02153073"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "For lipid parameters such as triglycerides (TG), total cholesterol (TC), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), Non-HDL- C, observed values (or converted values) and percent changes (%) from baseline in these  valuesare tabulated at each  observational point.", 
            "measure": "Changes from baseline in lipid parameters", 
            "safety_issue": "No", 
            "time_frame": "From Baseline and Month12"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}